Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

117.84
Delayed Data
As of Jul 02
 +0.27 / +0.23%
Today’s Change
51.93
Today|||52-Week Range
140.00
+21.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$10.1B

Company Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference. It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis, ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, ALN-APC for the treatment of hemophilia, and ALN-TMP for the treatment of hemoglobinopathies. Alnylam Pharmaceuticals was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Information

Alnylam Pharmaceuticals, Inc.
300 Third Street
Cambridge Massachusetts 02142
P:(617) 551-8200
Investor Relations:
(617) 551-8207

Employees

Shareholders

Mutual fund holders50.88%
Other institutional26.29%
Individual stakeholders25.49%

Top Executives

John M. MaraganoreChief Executive Officer & Director
Barry E. GreenePresident & Chief Operating Officer
Michael P. MasonTreasurer & Vice President-Finance
Rachel MeyersVice President-Research
Akshay K. VaishnawChief Medical Officer & Executive Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account